BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed SVA catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:e43cc5e8c1aacd6c5114@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:SVA P3 readout (est.): Immunogenicity and Safety of Rabies Vaccine 
 (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen
DESCRIPTION:Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Ce
 ll) in a Pre-exposure Prophylaxis Regimen\nNCT07055295 | PHASE3 | NOT_YET_
 RECRUITING | sponsor: Sinovac Biotech Co.\, Ltd\nPrimary completion date (
 ESTIMATED)\; top-line results usually follow later.\nTicker SVA (confidenc
 e 0.9)\nSource: https://clinicaltrials.gov/study/NCT07055295\nScheduling/r
 eference data from public records\; dates can move. Not investment\, legal
  or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07055295
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d0001037b97106e3c6b6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:SVA P3 readout (est.): Phase Ⅲ Trial of Group ACYW135 Meningococc
 al Conjugate Vaccine in Children Aged 12-23 Months
DESCRIPTION:Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccin
 e in Children Aged 12-23 Months\nNCT07505836 | PHASE3 | RECRUITING | spons
 or: Sinovac Biotech Co.\, Ltd\nPrimary completion date (ESTIMATED)\; top-l
 ine results usually follow later.\nDate precision: month (shown on the fir
 st day)\nTicker SVA (confidence 0.9)\nSource: https://clinicaltrials.gov/s
 tudy/NCT07505836\nScheduling/reference data from public records\; dates ca
 n move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07505836
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e7182b929a6c7e5e33ed@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:SVA P3 readout (est.): Immunogenicity and Safety of Rabies Vaccine 
 (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen
DESCRIPTION:Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Ce
 ll) in a Simulated Post-exposure Prophylaxis Regimen\nNCT07055893 | PHASE3
  | NOT_YET_RECRUITING | sponsor: Sinovac Biotech Co.\, Ltd\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nTicker SVA
  (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07055893\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07055893
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
